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Summary:
Background: The magnitude of initial drug resistance has important implications for the tuberculosis control
programme.
Aims: To study trend of initial drug resistance over a period of three decades in a rural community in five
panchayat unions in Chingleput district in south India.
Methods: A total population survey of tuberculosis in the area was undertaken in 1968-70, comprising
radiographic examination of all individuals aged 10 years or more and sputum examination of those with
abnormal shadows.  Subsequently, the total population survey was repeated on 6 occasions at intervals of 2.5
years along with new entrants found at each survey, and on two more occasions (1991-92, 1994-96) in a subset
of two panchayat unions.  Prevalence cases and (new) incidence cases of culture-positive tuberculosis were
identified in each survey, and their susceptibility to Isoniazid and Streptomycin was determined.
Results: Between 1968 and 1986, initial drug resistance to Isoniazid increased from 12.5% to 20.7% in
prevalence cases, at an average annual rate of 3.1%.  For Streptomycin, the increase was from 6.4% to 12.1%,
at the rate of 4.9% per annum.  In incidence cases, the corresponding annual rate of increase was 3.8% for
Isoniazid and 7.4% for Streptomycin.  In the subset of the population, that was surveyed in 1991-92 and 1994-
96, there was some evidence of a decline in the proportion of resistant cases after 1984-86.
Conclusion: There was a steady increase in the magnitude of initial drug resistance in the community between
1968 and 1986, which probably indicates an unsatisfactory tuberculosis programme during the period.
Key words: Initial drug resistance, Trend of drug resistance in community, Tuberculosis epidemiology
INTRODUCTION
The magnitude of drug resistance in
tuberculosis patients and changes in it over time are
useful indices for understanding the extent of resistant
bacterial transmission and for monitoring the
effectiveness of drug regimens in the area treatment
programme1.  Information on the former aspect is
widely available from out-patients attending
tuberculosis  clinics,2-11 but is difficult to obtain at the
community level, especially in a large developing
country such as India with limited resources.  An
excellent opportunity arose to do so from a very large
randomized trial of BCG vaccines, initiated in 1968,
in Chingleput district in south India12.  The Chingleput
population was followed for 15 years by frequent
surveys, that included new entrants also, selective
follow-up of high risk subjects and passive case
finding in subjects with chest symptoms who had
attended peripheral health centres.  All positive cultures
were tested for susceptibility to Isoniazid and
Streptomycin by standard methods in a well-
established laboratory with in-built quality assurance
techniques.  This report describes secular trends over
time in initial drug resistance (i.e., resistance amongst
untreated and treated patients combined), and also
assesses the impact of history of previous treatment
on the magnitude of resistance in the community.
_________
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MATERIAL  AND  METHODS
A tuberculosis prevalence survey, consisting
of radiographic examination of all individuals aged
10 years or more and sputum examination of those
with abnormal shadows, was undertaken in 1968-
70 in a population of about 100,000 persons in
Chingleput district in south India12.  The study area
comprised Thiruvallur town and five panchayat
unions (blocks) of  Ellapuram, Kadambathur, Poondi,
Thiruvallur and Thiruvalangadu.  The population
was followed for 15 years by repeat survey every
2.5 years, selective case finding (once every 10
months) amongst those with an abnormal
radiographic appearance or chest symptoms, and
passive case detection in those who spontaneously
attended peripheral health institutions with chronic
cough or chest pain.  Every repeat survey was
undertaken after updating the census through
registration of new entrants (e.g., newborns, settlers,
and those missed at the previous survey).  Thus,
prevalence cases were identified in seven total
population surveys (1968-70, 1971-73, 1973-75,
1976-78, 1979-81, 1981-83, 1984-86).  Excluding
those with a positive culture in each prevalence
survey, new cases in the rest of the populatioin were
identified in the following repeat survey (1971-73,
1973-75, 1976-78, 1979-81, 1981-83, 1984-86), and
were labeled as “incidence cases”.
In a subset of two blocks (Kadambathur
and Thiruvalangadu), two more surveys were
undertaken, one in 1991-92 and the other in 1994-
96, after an interval of 3.75 years13.  Prevalence
cases in the two surveys were identified, as also
incidence cases from the latter survey.  Finally, in
1999-2001, a prevalence survey was undertaken in
a random sample of the total population in the five
blocks14.  In the two subset    blocks (Kadambathur
and Thirvalangadu), all subjects (i.e., including those
not selected in the random sample) were investigated,
to facilitate comparisons with total population
surveys undertaken previously in these blocks.
All sputum specimens were examined by
fluorescence microscopy and cultured on
Lowenstein-Jensen medium.  Those yielding growth
were subjected to Streptomycin and Isoniazid
sensitivity tests and identification tests (niacin test,
growth at 250C, and para-nitrobenzoic acid test/
catalase test).
Details of procedures and techniques
employed for radiography, bacteriology and drug
sensitivity have been described earlier12.  In brief,
for all positive cultures and a control strain  (H37Rv)
in each batch, sensitivty tests were set up on
Lowenstein-Jensen medium employing concen-
trations of 0.1,0.2,1 and 5 mcg/ml for Isoniazid and
8,16,32 and 64 mcg/ml  for Streptomycin, and the
results were expressed as  minimal inhibitory
concentration (MIC) for the former, and resistance
ratio (RR) for the latter.
Definitions of resistance
A minimal inhibitory concentration (MIC)
of 5 or more was regarded as indicative of resistance
to Isoniazid, and a resistance ratio (RR) of 8 or more
as indicative of resistance to Streptomycin.
Statistical analysis
The findings were analyzed by sex and age
(10-24, 25-44, 45+ years), making the tacit
assumption that, within each of the 6 sex-age groups,
the findings in those not investigated would have
been the same as in those investigated.
Statistical methods included ÷2 tests for
differences and trends in proportions, weighted
regression analysis for estimating the annual rate of
increase and standardization employing the direct
method15 to adjust for differences in the age-sex
composition over time; the population in 1968-70
was taken as the standard population for the
prevalence surveys, and the population in 1971-73
for the incidence surveys.
RESULTS
Findings in the total population
Coverage by various investigations
In the various prevalence surveys, the
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coverage ranged from 82% to 90% for radiographic
examination, and from 88% to 96% for sputum
examination of eligible subjects.  In the subsequent
incidence surveys, the corresponding proportions
were 76% to 79%, and 91% to 97%, respectively.
Drug sensitivity tests were undertaken for 97% to
99.7% of the positive cultures in the prevalence
surveys and for 96% to 99.5% in the incidence
surveys.
Drug sensitivity in cases detected in prevalence
surveys
The number of patients who had drug
sensitivity tests ranged from 507 to 855 in the various
periods, the median being 744.  Over the years, there
was an increasing trend in the proportion of older
patients (i.e. 45 years or more) from 50.5% to 65.9%
(P<0.001).  To allow for these changes, an adjusted
estimate of the proportion with resistance was
computed (see page  3), and both observed and
adjusted estimates are set out in Table I, and the
latter illustrated in Figure l.
The observed prevalence of initial drug
resistance (in 1968-70) was 12.5% to Isoniazid and
6.4% to Streptomycin, including 4.6% to both drugs.
It tended to increase over the next 15 years to 20.7%
to Isoniazid in 1984-86(r=0.74, P=0.06) and to
12.1% to Streptomycin (r=0.96, P<0.001), including
9.4% to both drugs (r=0.90, P<0.01).  The annual
rate of incease was 3.1% for Isoniazid (95% C.I. 0.6-
5.6%), 4.9% for Streptomycin (95% C.I.3.6 - 6.2%),
and 5.3% for both drugs (95% C.I. 3.0-7.7%).
However, in the more recent survey, in 1999-
2001, the observed prevalence of Isoniazid resistance
was substantially less than that in the last three
surveys (1984-86, 1981-83, 1979-81), namely, 9.5%
compared to 20.7%, 21.4% and 19.9%, respectively
(P<0.001).  Further analyses showed that the
decrease in Isoniazid resistance was significant
(P<0.01) in males, whether aged less than 45 years
or 45 years or more.  In females also, there was
evidence of a decrease (P<0.05), but only in those
aged 45 years or more.
Adjustment by standardization for age and
sex did not have much effect, the difference between
the observed and standardized estimates being 0.5
or less in all instances for Streptomycin and all but
one instance for Isoniazid.
Drug sensitivity in cases detected in incidence
surveys
The  number of incidence cases with
sensitivity  results ranged from 520 to 709 in the
various  periods, the median being 554.  The
proportion of males was fairly stable over the
Table 1.   Drug resistance in cases detected in prevalence surveys (5 blocks)
Obs.=Observed; Std.=Standardized for sex and age; N.A.=Not available
Figure in brackets is the prevalence based on the random sample survey, while the other is based on all patients
tested.
Percentage of Patients with resistance to the following drug(s) 
 
Isoniazid 
 
Streptomycin 
 
Both drugs 
Period of 
Survey 
Total 
patients 
Obs.                 Std. Obs.                 Std. Obs.                  Std. 
1968-70 689 12.5                12.5   6.4                  6.4 4.6                     4.6 
1971-73 693 18.5                18.6   7.2                  7.2 5.9                     5.9 
1973-75 755 21.1                21.4   6.8                  6.9 5.3                     5.4 
1976-78 855 15.3                15.6   7.7                  8.0 5.0                     5.3 
1979-81 790 19.9                20.3 10.1                10.5 8.1                     9.7 
1981-83 832 21.4                21.5 10.9                11.0 7.9                     8.0 
1984-86 733 20.7                21.4 12.1                12.5 9.4                   10.0 
1999-01 507 
(442) 
9.5 9.9 
(9.7)                (9.9) 
N.A.                N.A. 
 
N.A.                 N.A. 
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years (P>0.1).   There was evidence of
heterogeneity in the distribution by age (P=0.02),
but no distinct trend was seen (P>0.2).  Both
observed and standardized estimates are set out in
Table 2, and the latter are illustrated in Figure 2.
Again, the difference between the two was small,
namely 0.5 or less in all instances for Streptomycin
and all but one instance for Isoniazid.
The proportion of resistant incidence cases
in 1971-73 was 6.3% to Isoniazid and 3.1% to
Streptomycin, including 1.7% to both drugs.  This
tended to increase with time, and was 10.0% to
Isoniazid in 1984-86 (r=0.63,P=0.2),6.0% to
Streptomycin (r=0.85, P=0.03), and 3.8% to both
drugs (r=0.87, P=0.03).  The annual rate of
increase was 3.8% for Isoniazid (95% C.I.-0.7%
- 8.6%), 7.4% for Streptomycin (95% C.I. 2.9 -
12.2%), and 8.0% to both drugs (95% C.I. 3.4 -
12.7%).
In every period, the proportion who were
resistant was substantially lower in incidence cases
(Table 2) than in prevalence cases (Table 1).  Thus,
the former was 31-47% of the latter for Isoniazid,
43-83% for Streptomycin and 29-61% for both
drugs.
Secular trends by age
There were no secular trends in resistance in
prevalence or incidence cases aged less than 25 years.
In cases aged 25 years or more, however, the
proportion with resistance increased significantly
(P<0.001) in prevalence cases from 12.4% in 1968-
TUBERCULOSIS  RESEARCH  CENTRE
Fig.1  Initial drug resistance in prevalence cases in 5 blocks
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Table 2.  Drug resistance in cases detected in incidence surveys (5 blocks)
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Table 3.  Drug resistance in the blocks surveyed more frequently
*Observed percentage, as the numbers were not large enough to permit standardization
**The larger number from this survey (343) is due to the observation period being longer (3.75 years) than in the
other surveys (2.5 years)
INH=Isoniazid; Strep=Streptomycin
Obs.=Observed; Std.=Standardized for sex and age
who were resistant increased from 6.2% in 1971-
73 to 9.9% in 1984-86 for Isoniazid (P=0.002), 2.8%
to 6.0% for Streptomycin (P<0.001), and 1.7% to
3.7% for both drugs  (P<0.001).
Secular trends by sex
There were no secular trends in females,
either in prevalence or incidence cases.  In males,
the proportion who were resistant in prevalence cases
increased from 12.6% in 1968-70 to 21.0% in 1984-
86 for Isoniazid (r=0.44, P=0.28), 6.3% to 12.8%
for Streptomycin (r=0.88, P<0.01), and 4.5% to
9.9% for both drugs (r=0.78, P= 0.04).  For incidence
cases, the proportion resistant increased from 6.7%
in 1971-73 to 8.3% in 1984-86 for Isoniazid, from
3.4% to 6.3% for Streptomycin, and from 1.9% to
3.4% for both drugs; however, none of the trends
was statistically significant.
Findings in the subset  population
In the subset of two blocks (Kadambathur
and Thiruvalangadu), prevalence surveys were
undertaken (on the total population present) on 10
occasions and incidence surveys on 7 occasions.
The findings with respect to drug sensitivity in this
more frequently surveyed population are set out in
Table  3 and illustrated in Figure 3.  In prevalence
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Percentage of patients with resistance to the following drug(s) 
           Isoniazid                   Streptomycin                Both drugs Period of survey Total patients 
Obs.                   Std. Obs.               Std. Obs.         Std 
1971-73 709   6.3 6.3 3.1 3.1 1.7 1.7 
1973-75 621   9.2 9.1   4.2 4.1 2.7 2.7 
1976-78 577   5.4 4.9 4.5 4.2 2.8 2.5 
1979-81 520 10.0 9.3 6.5 6.2 4.4 4.2 
1981-83 531 10.5 10.1  9.6 9.1 5.3 4.9 
1984-86 530 10.0 9.9 6.0 6.0 3.8 3.7 
 
Prevalence surveys Incidence surveys 
Resistant to the following drug(s)* Resistant to the following drug(s)* Period of survey Total  patients INH Strep Both 
Total 
patients INH Strep Both 
1968-70 189 10.6      5.8 3.2 ---- ---- ---- ---- 
1971-73 254 15.0      8.3 7.1 236 5.9 3.4 1.7 
1973-75 232 19.8      7.8 5.6 203 5.9 3.0 2.0 
1976-78 294 17.0      5.4 4.4 198 5.1 3.0 2.0 
1979-81 263 19.8      9.5 8.0 163 8.0 4.9 3.7 
1981-83 269 23.4    11.9 8.6 159    12.6 8.2 5.0 
1984-86 262 19.1    11.1 8.0 193 7.3 5.7 3.1 
1991-92 292 14.7    11.3 7.5 ---- ---- ---- ---- 
1994-96 238 11.3      6.3 3.4    343** 9.6 6.7 3.2 
1999-01 216 10.2     ---- ---- ---- ---- ---- ---- 
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cases, resistance to Isoniazid increased from 10.6%
in 1968-70 to 23.4% in  1981-83  (P=0.02) , to 70
to 20.5% in 1984-86 for Isoniazid, from 6.1% to
12.1% for Streptomycin, and from 4.4% to 9.3%
for both drugs.  In incidence cases, the proportions
Streptomycin from 5.8% to 11.9% (P=0.16), and
to both drugs from 3.2% to 8.6% (P=0.1).
Thereafter, there was some evidence of a  decline,
to 10.2% for Isoniazid by 1999-2001 (P=0.01), and
to 6.3% for Streptomycin and 3.4% to both drugs
by 1994-96 (P=0.2).
The findings in incidence surveys were
similar up to 1981-83 (Table 3).  The proportion
with Isoniazid resistance increased from 5.9%
to 12.6% (P = 0.1); the corresponding proportions
for Streptomycin resistance were 3.4% and 8.2%
(P= 0.08), and for double drug resistance were 1.7%
and 5.0%, respectively (P=0.02).  Thereafter, there
was a suggestion of a decrease up to 1994-96, but
it was not statistically significant (P>0.2).
Association between Age, Sex and Drug
Resistance
Cases in prevalence surveys
Drug resistance was appreciably less
common in cases of tuberculosis aged 45 years or
more than in cases aged 10 - 44 years (Table 4, upper
half).  In males, the proportions were 15.1% and
21.0% for Isoniazid, 7.4% and 10.6% for
Streptomycin, and 5.0% and 8.6%, respectively, for
double drug resistance, all the differences being
statistically significant (P<0.001). In females also,
the contrasts were significant (P<0.01), the
corresponding proportions being 13.0% and 20.1%
for Isoniazid, 6.6% and 11.8% for Streptomycin, and
5.0% and 9.5% for both drugs.
In patients of the same  age, there were no
differences between males and females (P>0.2).
Cases in incidence surveys
In males, drug resistance tended to decrease
significantly with age (Table 4, lower half).  Thus,
the proportions with resistance in cases aged 10-24,
25-44 and 45+ years were 13.1%, 11.3% and 6.4%,
respectively , for Isoniazid (P<0.001), 7.9%, 7.3%
and 3.8% for Streptomycin (P<0.001), and 4.9%,
4.0% and 2.4% for both drugs (P<0.02).  In female
cases, however, there was no association.Among
patients of the same age, there were no differences
between males and females.
TUBERCULOSIS  RESEARCH  CENTRE
Fig 2.  Initial drug resistance in incidence cases in 5 blocks
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Fig.3.  Initial drug resistance in prevalence cases in 2 blocks
Fig. 4.  Initial drug resistance in incidence cases in 2 blocks
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History of previous chemotherapy and its effect
on drug resistance
Inquiry regarding previous treatment for
tuberculosis was undertaken in over 99% of the
patients in only four of the ten prevalence surveys;
in these, the sensitivity tests results were related to
the presence (or absence) of any previous history of
chemotherapy (Table 5).  Drug resistance was
invariably more frequent in patients with a history of
previous chemotherapy than in those without, the
Relative Risk (RR) for Isoniazid resistance being 6.5
in 1971-73 (P<0.001), 2.1 in 1991-92 (P=0.04), 3.4
in 1994-96 (P<0.01) and 1.5 in 1999-2001 (P>0.2).
The corresponding RRs for Streptomycin resistance
were 4.5 (P< 0.001), 2.3 (P=0.05) and 3.3 (P=0.05),
respectively, in the first three surveys.
Similar findings were obtained in one more
survey (1973-75), where only 67% of the cases had
been interrogated regarding  previous treatment, the
RRs for those with  previous chemotherapy being
8.1 for Isoniazid (P<0.001), 2.6 for Streptomycin
(P=0.05), and 6.0 for both drugs combined (P<0.01).
In the remaining five surveys, either the proportion
who had a history elicited or the number with a
history of previous treatment was too low to permit
valid comparisons.
History of previous treatment was obtained
for over 90% of cases in only one (1971-73) of the
incidence surveys.  Resistance was higher in those
with a history of previous treatment than in those
without (Table 5), the proportions resistant being
23.5% and 4.2% for Isoniazid (RR=5.6, P<0.001),
and 5.9% and 2.8% for Streptomycin (RR=2.1,
P>0.2) In another survey (1973-75), history was
taken in 71% of cases, and the corresponding
proportions were 23.7% and 6.8% for Isoniazid
(RR=3.5, P<0.001), and 10.2% and 3.6% for
Streptomycin (RR = 3.9, P = 0.01).  In the remaining
four incidence surveys, the proportion that had
history elicited was too low (47-55%) to provide
valid comparisons.
Primary Isoniazid resistance, that is, the
prevalence of Isoniazid resistance in patients with
no history of previous treatment, varied appreciably
between 5.1% and 12.6% in the four prevalence
surveys (P<0.01), but showed no trend (Table 5).
The corresponding proportion for primary
Streptomycin resistance was 3.0%, 9.4% and 3.1%
(P<0.001) in the three surveys with sensitivity tests
to Streptomycin.  In the 1971-73 incidence survey,
the prevalence of primary resistance was 4.2% to
Isoniazid and 2.8% to Streptomycin (Table 5).
DISCUSSION
The magnitude of drug resistance prevalent
in a community can have significant implications
for the outcome of a tuberculosis programme,
because patients with drug-resistant bacilli respond
much less favourably than those with sensitive bacilli.
Also, ‘failure’ of treatment cases in both the groups
would  infect  the non-infected with drug-resistant
bacilli and render treatment ineffective in them.  It
is, therefore, important for programme managers
to monitor the level of drug resistance in the
community, and adopt appropriate treatment
regimens.  Resistance could be primary, i.e., infection
from a source with resistant bacilli, or acquired due
to inappropriate drug  prescription, irregular drug
supply to patients or non-compliance on the part of
patients. The accuracy of  classification, as primary
or acquired, depends on the efficiency with which
history of previous treatment is elicited.  This is
TRENDS  IN  INITIAL  DRUG  RESISTANCE
Table 6.  Primary drug resistance in outpatients
   at the Tuberculosis Research Centre,
   Chennai
INH=Isoniazid  Strep.=Streptomycin
% resistant to the 
following Period 
No. of 
patients 
INH Strep Both 
1957-60 498    5.2    3.1 1.1 
1961-64 776    5.4    5.9 1.9 
1965-68 692    7.2    7.0 3.1 
1969-72 896    9.2    7.9 3.6 
1973-76 940 11.4 12.5 5.9 
1977-80 748    9.8    7.9 4.1 
1981-84 825 10.9 11.6 6.1 
1985-88 449 12.2 10.9 6.9 
1989-92 356 15.7 13.5 7.0 
1993-96 313 15.0 11.8 7.7 
1997-00 330 10.3    7.9 3.3 
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often poor in developing countries because medical
prescriptions are seldom available, patients are
unaware of details of their treatment or sometimes
conceal them, and skills for eliciting an accurate
history are not always forthcoming.  Therefore, the
estimated drug resistance in surveys is usually a
mixture of primary and acquired resistance, and is
often referred to as “initial drug resistance”1.
Estimates of primary drug resistance
are available over four decades in intensively
questioned outpatients attending the
Tuberculosis Research Centre, Chennai (Table
6).  Primary Isoniazid resistance increased from
5.2% in 1957-60 to 15.0% in 1993-96, at the
rate of 3.1% per annum, Streptomycin
resistance from 3.1% to 11.8% at the rate of
3.3% per annum, and double drug resistance
from 1.1% to 7.7% at the rate of 5.1% per
annum.  Not all of this increase  may be real, as
there is a possibility of methodological
differences over time.  Thus, at this Centre, only
patients with no history of previous chemotherapy
are offered treatment in randomized clinical trials
following intensive inquiry, initially by two physicians
and a medical social worker, and a month later (after
some confidence building has taken place) by a
physician.  It is possible that, in their anxiety to avoid
being turned away from a reputed institution,
patients became increasingly adept, over the years,
in concealing details of previous treatment, and this
could have resulted in higher proportions with
resistance in later years.
A one-time study, in 1964-65, in nine urban
centres in the country2 found the prevalence of
primary drug resistance to be 14.7% to Isoniazid
(range 11-20%) and 12.5% to Streptomycin (range
8-20%), including 6.5% to both drugs (range 4-
11%).  Other studies in Chennai4, Gujarat5 and North
Arcot district11 yielded a range of 8-19% for Isoniazid
and 7-11% for Streptomycin, including 4-7% to both
the drugs.
A one-time survey of all patients, previously
treated or untreated, in nine urban centres in the
country3 in 1965-67 showed that the prevalence of
initial drug resistance varied from 15% to 69% for
Isoniazid (median 23%) and 12% to 63% for
Streptomycin (median 19%), including a range of
5% to 58% for both the drugs (median 11%).  Other
studies in Bangalore6, Kolar7, New Delhi8, Jaipur9,
Pondicherry10, North Arcot district10 and Raichur
district11 yielded a range of 10-33% for Isoniazid,
 5-18% for Streptomycin, including 2-13% for both.
A state-wide study in 1997 in Tamil Nadu, involving
145 participating centres, showed that the proportion
with initial Isoniazid resistance was 15.4%17.
District-wise studies in 1999 showed that initial
Isoniazid resistance was 23.4% in North Arcot and
18.7% in Raichur, the corresponding figures for
initial Stretomycin resistance being 12.4% and 7.1%,
respectively.
In our community study in Tamil Nadu, the
initial drug resistance (primary plus acquired) in
1968-70 was 12.5% to Isoniazid and 6.4% to
Streptomycin, including 4.6% to both the drugs.
The initial drug resistance increased annually by
3.1%, 4.9% and 5.3%, respectively.  The increases
probably reflect an ineffective tuberculosis control
programme during this period.  A study from Korea18
reported that the prevalence of drug resistance
increased from  38% in 1965 to 48% in 1980, but
dropped to 25% in 1990, the decrease coinciding
with treatment efficiency increasing from 60% in
1984 to 77% in 1989.  In  New York City, an
intensive treatment programme resulted in a 29%
decrease, over a  3-year period, in the prevalence of
drug resistance19.
Initial drug resistance was observed less
frequently in incidence cases than in prevalence
cases, which is not surprising as they were new
cases that developed in subjects with no disease
previously, and were, therefore, less likely to
have received previous chemotherapy.  However,
even among them, there was some evidence of
increase over time in initial drug resistance, by
3.8% per annum for Isoniazid and 7.4% per
annum for Streptomycin. During the same period
(1971-86), the level of primary drug resistance in
intensively interviewed out-patients attending the
Tuberculosis Research Centre was substantially
smaller and the rate of increase over time was also
appreciably smaller, namely, 1.8% per annum for
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Isoniazid and 1.5% for Streptomycin.  These
differences suggest that while the monitoring
of the level of initial drug resistance in out-
patients attending a tuberculosis centre could
be of considerable value to the programme
manager, especially for choosing appropriate
drug regimens, it may not be a satisfactory tool
to understand the epidemiological situation with
respect to change in the rate of resistance
transmission in the community.
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